47 / 70
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 30, No 5, September/October 2019
AFRICA
289
8.
Kirma C, Erkol A, Pala S, Oduncu V, Du¨ndar C, Izgi A,
et al.
Intracoronary bolus-only compared with intravenous bolus plus infu-
sion of tirofiban application in patients with ST-elevation myocar-
dial infarction undergoing primary percutaneous coronary intervention.
Catheter Cardiovasc Interv
2011;
79
: 59–67.
9.
O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de
Lemos JA,
et al
. 2013 ACCF/AHA guideline for the management of
ST-elevation myocardial infarction: a report of the American College
of Cardiology Foundation/American Heart Association Task Force on
Practice Guidelines.
Circulation
2013;
127
: 362–425.
10. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG,
Holmes DR Jr,
et al.
2014 AHA/ACC guideline for the management of
patients with non-ST-elevation acute coronary syndromes: a report of
the American College of Cardiology/American Heart Association task
force on practice guidelines.
Circulation
2014;
130
: 344–426.
11. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti
F,
et al
. 2015 ESC guidelines for the management of acute coronary
syndromes in patients presenting without persistent ST-segment eleva-
tion: task force for the management of acute coronary syndromes in
patients presenting without persistent ST-segment elevation of the
European Society of Cardiology (ESC).
Eur Heart J
2016;
37
: 267–315.
12. Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C,
Borger MA,
et al
. ESC guidelines for the management of acute myocar-
dial infarction in patients presenting with ST-segment elevation.
Eur
Heart J
2012;
33
: 2569–619.
13. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD,
the writing group on behalf of the joint ESC/ACCF/AHA/WHF task
force for the universal definition of myocardial infarction: Third universal
definition of myocardial infarction.
Eur Heart J
2012;
33
: 2551–2556.
14. TIMI study group. The Thrombolysis in Myocardial Infarction (TIMI)
trial: phase I findings.
N Engl J Med
1985;
312
(14): 932–936.
15. Van ‘t Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ,
Zijlstra F. Angiographic assessment of myocardial reperfusion in
patients treated with primary angioplasty for acute myocardial infarc-
tion: myocardial blush grade. Zwolle myocardial infarction study group.
Circulation
1998;
97
: 2302–2306.
16. Bilsel T, Akbulut T, Yesilcimen K, Terzi S, Sayar N, Dayi SU,
et al
.
Single high-dose bolus tirofiban with high-loading-dose clopidogrel in
primary coronary angioplasty.
Heart Vessels
2006;
21
: 102–107.
17. Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A,
et
al.
. 2014 ACC/AHA key data elements and definitions for cardiovascu-
lar endpoint events in clinical trials: A report of the American College
of Cardiology/American Heart Association task force on clinical data
standards (writing committee to develop cardiovascular endpoints data
standards).
Circulation
2015;
132
(4): 302–361.
18. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J,
et al
. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I:
A comparison between intravenous tissue plasminogen activator and
intravenous streptokinase. Clinical findings through hospital discharge.
Circulation
1987;
76
: 142–154.
19. Zalewski J, Nycz K, Przewlocki T,
et al.
Evolution of myocardial
perfusion during primary angioplasty in spontaneously reperfused
infarct-related artery: impact on long-term clinical outcomes and left
ventricular function recovery.
Int J Cardiol
2011;
147
: 25–31.
20. Ding S, Pu J, Qiao ZQ,
et al
. TIMI myocardial perfusion frame count:
a new method to assess myocardial perfusion and its predictive value
for short-term prognosis.
Catheter Cardiovasc Interv
2010;
75
: 722–732.
21. Mokadam NA, Melford RE Jr, Maynard C,
et al
. Prevalence and proce-
dural outcomes of percutaneous coronary intervention and coronary
artery bypass grafting in patients with diabetes and multivessel coronary
artery disease.
J Card Surg
2011;
26
: 1–8.
22. Timmer JR, Ten Berg J, Heestermans AA,
et al
. Pre-hospital admin-
istration of tirofiban in diabetic patients with ST-elevation myocardial
infarction undergoing primary angioplasty: a subanalysis of the on-time
2 trial.
EuroIntervention
2010;
6
: 336–342.
23. Kunichika H, Ben-Yehuda O, Lafitte S, Kunichika N, Peters B,
DeMaria AN. Effects of glycoprotein IIb/IIIa inhibition on microvascu-
lar flow after coronary reperfusion. A quantitative myocardial contrast
echocardiography study.
J Am Coll Cardiol
2004;
43
: 276–283.
24. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE,
Neumann FJ,
et al
. Abciximab as adjunctive therapy to reperfusion in
acute ST-segment elevation myocardial infarction: a meta-analysis of
randomized trials.
J Am Med Assoc
2005;
293
: 1759–1765.
25. Topol EJ, Moliterno DJ, Hermann HC,
et al
. Comparison of two
platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the
prevention of ischemic events with percutaneous coronary revasculari-
zation.
N Engl J Med
2001;
344
: 1888–1894.
26. Sharma S, Makkar R, Lardizabal J. Intracoronary administration of
abciximab during percutaneous coronary interventions: should this be
the routine and preferred approach?
J Cardiovasc Pharmacol Ther
2006;
11
: 136–141.
27. Hu S, Wang H, Zhu J, Li M, Li H, Gao D, Zhang H. Effect of intra-
coronary administration of tirofiban through aspiration catheter on
patients over 60 years with ST-segment elevation myocardial infarction
undergoing percutaneous coronary intervention.
Medicine
(Baltimore)
2018;
97
(21): e10850.
28. Wilmer CI. Intracoronary high-dose bolus tirofiban administration
during complex coronary interventions: A United States-based case
series.
Cardiovasc Revasc Med
2018;
19
(1 Pt B): 112–116.
29. Zalewski J, Nycz K, Przewlocki T,
et al.
Evolution of myocardial
perfusion during primary angioplasty in spontaneously reperfused
infarct-related artery: impact on long-term clinical outcomes and left
ventricular function recovery.
Int J Cardiol
2011;
147
: 25–31.
30. Huang SS, Leu HB, Lu TM,
et al
. The impacts of in-hospital invasive
strategy on long-term outcome in elderly patients with non-ST-elevation
myocardial infarction.
Acta Cardiol Sin
2013;
29
: 115–123.
31. PROVE IT–TIMI 22 investigators. C-reactive protein levels and
outcomes after statin therapy.
N Engl J Med
2005;
352
: 20–28.
32. Ridker PM, Hennekens CH, Buring JE,
et al
. C-reactive protein and
other markers of inflammation in the prediction of cardiovascular
disease in women.
N Engl J Med
2000;
342
: 836–843.
33. Saltzman AJ, Mehran R, Hooper WC, Moses JW, Weisz G, Collins MB,
et al
. The relative effects of abciximab and tirofiban on platelet inhibi-
tion and C-reactive protein during coronary intervention.
J Invasive
Cardiol
2010;
22
(1): 2–6.
34. Ercan E, Tengiz I, Duman C, Onbasili OA, Baris N. Effect of tirofiban
on C-reactive protein in non-ST-elevation myocardial infarction.
Am
Heart J
2004;
147
(1): e1.